The performance was driven by strong growth in the US generics business that saw a 32 percent on year increase in sales.

Despite decades of research, multiple myeloma remains an incurable disease. A wide array of therapies, such as proteasome ...

From innovation in manufacturing to more-flexible regulation and better communication with payers, much needs to happen to ...

An estimated 1·6 million adolescents (aged 10–19 years) were living with HIV in 2024, with adolescents having lower rates of ...

WinRevair’s Phase 3 HYPERION trial was stopped early for efficacy, with positive top-line results announced in the month ...

Syndax Pharmaceuticals (NASDAQ:SNDX) posted GAAP revenue of $38.0 million in Q2 2025 and far above analyst estimates. GAAP net loss per share was $ (0.83) for Q2 2025, a narrower GAAP loss than the $ ...

Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that it has expanded its existing relationship and amended ...

The FDA formally kicked off its quinquennial process to reauthorize the federal user fee legislation that helps fund its ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the second quarter ended ...

Expanding Global Footprint: As the only publicly listed psychedelics company with a sustainable source of ibogaine in Africa, we are uniquely positioned to lead in ethical, scalable, and locally ...

Detailed price information for Vanda Pharmaceuticals (VNDA-Q) from The Globe and Mail including charting and trades.

Discover how BioCryst achieved record Q2 2025 results with ORLADEYO's 45% revenue growth, strategic moves, and confident leadership transition.